ANAPTYSBIO, INC. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- ANAPTYSBIO, INC. payments for repurchase of common stock for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- ANAPTYSBIO, INC. payments for repurchase of common stock for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- ANAPTYSBIO, INC. payments for repurchase of common stock for the quarter ending 2025-12-31 was $3.38M, a 642.11% increase year-over-year.
- ANAPTYSBIO, INC. payments for repurchase of common stock for the quarter ending 2025-09-30 was $9.72M.
- ANAPTYSBIO, INC. payments for repurchase of common stock for fiscal 2025 was $68.63M, a 14949.56% increase from fiscal 2024.
- ANAPTYSBIO, INC. payments for repurchase of common stock for fiscal 2024 was $456.00K, a 99.09% decline from fiscal 2023.
- ANAPTYSBIO, INC. payments for repurchase of common stock for fiscal 2023 was $50.00M.
- ANAPTYSBIO, INC. payments for repurchase of common stock for fiscal 2022 was $0.00.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | $13.10M derived: sum of 4 quarters · filed 2026-09-21 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $64.20M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-12-31 | $3.38M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $68.63M 10-KT · filed 2026-09-21 |
| 2025-09-30 | $9.72M derived: 10-Q 9 month − 10-KT 6 month · filed 2025-11-04 | $65.70M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-06-30 | $51.10M derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | $55.98M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-03-31 | $4.42M 10-Q · filed 2026-05-12 | $4.88M derived: sum of 4 quarters · filed 2026-09-21 |
| 2024-12-31 | $456.00K derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $456.00K 10-KT · filed 2026-09-21 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $0.00 derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-05 | $12.47M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $50.00M 10-K · filed 2026-03-03 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $50.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $12.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $50.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $37.53M 10-Q · filed 2024-05-09 | $37.53M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | |
| 2021-12-31 | $0.00 10-K · filed 2024-03-11 | |
| 2018-12-31 | $0.00 10-K · filed 2019-02-28 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $0.00 10-K · filed 2019-02-28 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $0.00 derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $0.00 derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-12 | $0.00 derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $1.00K 10-K · filed 2019-02-28 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | |
| 2016-03-31 | $1.00K 10-Q · filed 2017-05-12 | |
| 2015-12-31 | $0.00 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |